Tepotinib plus osimertinib in patients with EGFR-mutated non-small-cell lung cancer with MET amplification following progression on first-line osimertinib (INSIGHT 2): a multicentr... by Wu, Yi-Long, Prof, Guarneri, Valentina, Prof, Voon, Pei Jye, MD, Lim, Boon Khaw, MRCP, Yang, Jin-Ji, Prof, Wislez, Marie, Prof, Huang, Cheng, Prof, Liam, Chong Kin, Prof, Mazieres, Julien, Prof, Tho, Lye Mun, PhD, Hayashi, Hidetoshi, Prof, Nhung, Nguyen Viet, PhD, Chia, Puey Ling, PhD, de Marinis, Filippo, Prof, Raskin, Jo, MD, Zhou, Qinghua, Prof, Finocchiaro, Giovanna, MD, Le, Anh Tuan, PhD, Wang, Jialei, Prof, Dooms, Christophe, PhD, Kato, Terufumi, PhD, Nadal, Ernest, PhD, Hin, How Soon, Prof, Smit, Egbert F, Prof, Wermke, Martin, Prof, Tan, Daniel, PhD, Morise, Masahiro, PhD, O'Brate, Aurora, PhD, Adrian, Svenja, MD, Pfeiffer, Boris M, MD, Stroh, Christopher, PhD, Juraeva, Dilafruz, PhD, Strotmann, Rainer, MD, Goteti, Kosalaram, MD, Berghoff, Karin, MD, Ellers-Lenz, Barbara, MSc, Karachaliou, Niki, MD, Le, Xiuning, MD, Kim, Tae Min, Prof

Get full text

Site-specific therapy guided by a 90-gene expression assay versus empirical chemotherapy in patients with cancer of unknown primary (Fudan CUP-001): a randomised controlled trial by Liu, Xin, MD, Zhang, Xiaowei, MD, Jiang, Shiyu, MD, Mo, Miao, MM, Wang, Qifeng, MD, Wang, Yanli, MM, Zhou, Liangping, MD, Hu, Silong, MD, Yang, Huijuan, Prof, Hou, Yifeng, MD, Chen, Yong, Prof, Lu, Xueguan, MD, Wang, Yu, MD, Zhou, Xiaoyan, Prof, Li, Wentao, MD, Chang, Cai, Prof, Yang, Xiujiang, MD, Chen, Ke, MD, Cao, Jun, MD, Xu, Qinghua, PhD, Sun, Yifeng, MSc, Luo, Jianfeng, MD PhD, Luo, Zhiguo, MD, Hu, Xichun, Prof

Get full text